Formoterol fumarate inhalation solution (Perforomist™) for COPD

Jeffrey B. Rubins

Research output: Contribution to journalArticlepeer-review

Abstract

Formoterol fumarate is an effective treatment for chronic obstructive pulmonary disease (COPD) patients with moderate or greater severity of airflow obstruction. Published studies indicate that formoterol has a rapid onset of bronchodilation, which may enhance compliance, and sustained bronchodilation over 12 h, which produces a cumulative effect when inhaled twice daily. With long-term use, formoterol fumarate increases trough forced expiratory volume in 1 s and improves measures of hyperinflation, which correlate with relief of symptoms and a decreased need for additional short-acting bronchodilators as rescue treatment. The combination of formoterol with anticholinergic bronchodilators, especially the long-acting anticholinergic tiotropium, appears to further improve bronchodilation, decrease hyperinflation, improve symptoms and decrease the need for rescue therapy, compared with either agent alone. The availability of formoterol fumarate inhalation solution (Perforomist™) for treatment of COPD now extends these benefits to patients who prefer nebulizer therapy and/or cannot use metered-dose or dry-powder inhalers effectively.

Original languageEnglish (US)
Pages (from-to)415-423
Number of pages9
JournalExpert Review of Clinical Immunology
Volume4
Issue number4
DOIs
StatePublished - Jul 1 2008

Keywords

  • Bronchodilator
  • COPD
  • Formoterol fumarate
  • Nebulization
  • β-agonist

Fingerprint Dive into the research topics of 'Formoterol fumarate inhalation solution (Perforomist™) for COPD'. Together they form a unique fingerprint.

Cite this